Pharvaris (NASDAQ:PHVS) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research began coverage on shares of Pharvaris (NASDAQ:PHVS) in a research report sent to investors on Wednesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $42.00 target price on the stock.

A number of other equities research analysts also recently weighed in on PHVS. Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Wedbush raised their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded Pharvaris from a “hold” rating to a “sell” rating in a research note on Sunday, April 5th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.73.

Pharvaris Stock Performance

NASDAQ:PHVS opened at $26.63 on Wednesday. Pharvaris has a 1 year low of $11.66 and a 1 year high of $29.85. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -7.90 and a beta of -2.58. The business has a fifty day moving average of $27.05 and a 200-day moving average of $25.52.

Insider Activity

In related news, CEO Berndt Modig sold 23,333 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $27.74, for a total value of $647,257.42. Following the sale, the chief executive officer directly owned 142,084 shares of the company’s stock, valued at $3,941,410.16. This trade represents a 14.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 11.84% of the stock is owned by insiders.

Institutional Trading of Pharvaris

Several large investors have recently modified their holdings of PHVS. GF Fund Management CO. LTD. bought a new stake in Pharvaris during the 4th quarter valued at approximately $35,000. Barclays PLC purchased a new position in shares of Pharvaris during the fourth quarter valued at approximately $77,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Pharvaris during the third quarter valued at approximately $75,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Pharvaris during the fourth quarter valued at approximately $86,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the last quarter.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $42 price target (~58% upside vs. current levels), which can boost investor interest and buying pressure. Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation
• Positive Sentiment: Wedbush raised its price target on PHVS to $42, aligning with other bullish voices and reinforcing the street’s constructive view on Pharvaris’ growth/valuation runway. Wedbush Increases Pharvaris (NASDAQ:PHVS) Price Target to $42.00
• Neutral Sentiment: HC Wainwright published earnings/long‑term model commentary for Pharvaris (estimating FY2030 figures and Q1 outlook). Analyst model updates can influence expectations but are not an immediate catalyst absent new clinical or commercial data. HC Wainwright Predicts Pharvaris FY2030 Earnings
• Neutral Sentiment: Reported short-interest data is effectively zero (no measurable short volume), so short-covering or squeeze dynamics are unlikely to be a driver in the near term. (Internal reporting entry.)
• Negative Sentiment: CEO Berndt Modig sold 23,333 shares (~14.1% reduction in his reported position) under a pre-arranged Rule 10b5-1 plan for proceeds ~ $647k. Insider sales can be interpreted negatively by some investors even when executed under 10b5-1 plans. SEC filing for insider sale

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.